PresentationGreat. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 44th Annual Healthcare Conference today with Jazz. First, you're going to hear a presentation from the company's CEO, and then we're going to go into some Q&A. So if you're sitting in the room and you have a question, just raise your hand and we'll bring you a microphone or you can always submit them online to me, and I can read them up here.Renée GaláPresident, CEO & Director Great. ...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) FY Conference January 13, 2026 02:15 PM ET Company ParticipantsRob Iannone - CMOPhilip Schlom - CFORenée Galá - CEOConference Call ParticipantsNone - AnalystJessica Fye - AnalystJessica FyeGreat. Good afternoon, everyone. My name is Jessica Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 44th Annual Healthcare Conference today with Jazz. First, you're going to hear a presentation from the company CEO, and then we're going to go into some Q&A. So if you'r ...

January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala, President & CEO Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the ability of the Company's portfolio to drive long-term shareholder value; ...

Needham analyst Ami Fadia raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $235 from $210 and keeps a Buy rating on the shares. The firm cites the company having presented the HERIZON-GEA-01 study with additional color on the subgroup analysis, noting that the overall data favored zani treatment arms across all subgroups with a longer tail on PFS for tislelizumab arm and slightly higher efficacy in TAP under 1% over TAPat 1% or higher. A key opinion leader on the call also noted that the be ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K (Exact name of registrant as specified in its charter) Ireland 001-33500 98-1032470 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.) Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7 (Address of principal executive offices, including zip code) 011-353-1-634-7800 (Registrant's telephone number, including area code) Check the appropriate box below if th ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic clinical collaboration with Jazz Pharmaceuticals (Nasdaq: JAZZ) on the exploration of a novel combination therapy for patients with HER2-positive breast cancer. As part of this collaboration, the partners will initiate a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial, evaluating the combination ...

PresentationGood morning and welcome to the zanidatamab HERIZON-GEA-01 Investor Call and Webcast. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Renee Gala, President and Chief Executive Officer of Jazz Pharmaceuticals. Thank you. Please go ahead.Renée GaláPresident, CEO & Director Good morning, everyone. My name is Renee Gala, President and CEO of Jazz Pharmaceuticals. Thank you for joining us. Before I begin, please note that today' ...

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure:I/we ...

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure:I/we ...

Summary of Jazz Pharmaceuticals Investor Call on Zanidatamab Horizon-GEA-01 Company and Industry - **Company**: Jazz Pharmaceuticals (NasdaqGS:JAZZ) - **Industry**: Oncology, specifically focusing on HER2-positive gastroesophageal adenocarcinoma (GEA) Core Points and Arguments 1. **Clinical Trial Presentation**: Jazz Pharmaceuticals presented data from the phase III Horizon-GEA-01 Clinical Trial at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, focusing on zanidatamab in combination with chemotherapy for HER2-positive GEA patients [2][4] 2. **Efficacy of Zanidatamab**: The trial demonstrated a 35% reduction in the risk of disease progression or death, translating to over four months of improvement in median progression-free survival (PFS) compared to trastuzumab plus chemotherapy [7][24] 3. **Overall Survival Benefits**: There was a statistically significant 28% reduction in the risk of death for zanidatamab plus tislelizumab plus chemotherapy versus trastuzumab, leading to a more than seven-month improvement in median overall survival (OS) [8][24] 4. **Mechanism of Action**: Zanidatamab is a bispecific antibody targeting two extracellular domains of HER2, which differentiates it from traditional therapies and enhances its efficacy [22][23] 5. **Safety Profile**: The safety profile of zanidatamab was consistent with known profiles of the individual treatments, although there was an increase in grade three or more toxicities in zanidatamab-containing arms [18][19] 6. **Regulatory Plans**: Jazz Pharmaceuticals plans to submit a supplemental biologics license application in the first half of the year and seeks inclusion in NCCN guidelines based on the trial results [21][33] Additional Important Content 1. **Patient Demographics**: The trial included 914 patients, with approximately 50% enrolled from Asia and 80%-85% of tumors being HER2 IHC3+ [12][13] 2. **Adverse Events**: Infusion-related reactions occurred in 25% of patients receiving zanidatamab, compared to 13.2% for trastuzumab, indicating a need for careful monitoring [18] 3. **Market Opportunity**: GEA is the fifth most common cancer globally, with a significant unmet need for effective HER2-targeted therapies, as the last new option was introduced in 2010 [30][31] 4. **Commercial Strategy**: Jazz Pharmaceuticals is positioned to leverage existing infrastructure for a rapid launch of zanidatamab if approved, with a focus on the strong data supporting its efficacy [31][32] 5. **Future Development**: The company is exploring zanidatamab in various HER2-positive solid tumors, indicating a robust pipeline and potential for broader applications [29][28] This summary encapsulates the key points discussed during the investor call, highlighting the promising data for zanidatamab and its potential impact on the treatment landscape for HER2-positive GEA.